- Wuxi Biortus Biosciences Co. Ltd., a Wuxi, China-based leader in structural biology service for drug discovery, closed a US$15m Series A financing
- The round was led by Bayland Capital
- The company intends to use the funds to establish a global cryo-EM innovation center
- Biortus is a full-scale contract research organization (CRO) for lead generation in drug discovery, offering services in critical aspects
- The research hub is under construction at Wuxi International Life Science Innovation Campus (I·Campus) in collaboration with Wuxi Municipal Government
- In the next 3 years, Biortus Cryo-EM will add at least 5 units of high-end electron microscopes to further expand its capacity
